Alzheimer’s disease is commonly thought of as an older person’s illness. But new research from Columbia University and the ...

Dementia biomarkers -- phosphorylated tau (P-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) - ...

A new study from Columbia University Mailman School of Public Health and the Columbia Butler Aging Center suggests that risk ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

In a large Swedish study, researchers found that the environmentally sustainable EAT-Lancet diet does not increase dementia ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

Radford, M.D., at Mayo Clinic studies the differences in dementia between Caucasians and African Americans to develop interventions.

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...